The HIV capsid protein plays a critical role
in the virus' life cycle. Mizzou researchers recently developed the most
complete model yet of this vital protein.
Credit: Karen Kirby and Anna Gres, Bond Life Sciences Center
HIV, or human immunodeficiency virus, is the
retrovirus that leads to acquired immunodeficiency syndrome or AIDS.
Globally, about 35 million people are living with HIV, which constantly
adapts and mutates creating challenges for researchers. Now, scientists
at the University of Missouri are gaining a clearer idea of what a key
protein in HIV looks like, which will help explain its vital role in the
virus' life cycle. Armed with this clearer image of the protein,
researchers hope to gain a better understanding of how the body can
combat the virus with the ultimate aim of producing new and more
effective antiviral drugs.
In recent years, scientists have used various techniques to determine
the structure of the capsid protein, which is the building block of an
inner shell of HIV. Until now, the clearest image had been of a mutated
protein. Stefan Sarafianos, an associate professor of molecular
microbiology and immunology and the Chancellor's Chair of Excellence in
molecular virology in the University of Missouri School of Medicine, and
his team captured long sought detailed images of the capsid protein in
its natural state.
"The capsid shell acts as an 'invisibility cloak' that hides the
virus' genetic information, the genome, while it is being copied in a
hostile environment for the virus," said Sarafianos, who also holds an
appointment in the Department of Biochemistry in the College of
Agriculture, Food and Natural Resources and serves as a researcher at
the Bond Life Sciences Center. "Fine-tuned capsid stability is critical
for successful infection: too stable a capsid shell and the cargo is
never delivered properly; not stable enough and the contents are
detected by our immune defenses, triggering an antiviral response.
Capsid stability is a key to the puzzle, and you have to understand its
structure to solve it."
Sarafianos and his team created the most complete model yet of an HIV
capsid protein. The research team used a technique called X-ray
crystallography to unravel the protein's secrets. By taking many copies
of the protein, they coaxed them into forming a patterned, crystalline
lattice (see photo).
"With X-ray crystallography, the biggest challenge is to get protein
crystals of good quality that will allow researchers to accurately study
the protein," said Anna Gres, an MU graduate student in the Department
of Chemistry and first author of the study. "Sometimes this process can
take years, but by using advanced techniques, we were able to cut that
down considerably."
Next they shot high-powered X-ray beams at the crystal. By
interpreting how the X-rays scattered when they ricocheted off the
proteins, the researchers made a 3-D map of the protein. "But the 3-D
map doesn't make sense until we make an atomic model of the protein to
fit in that map," said Karen Kirby, a research scientist at Bond LSC and
co-author of the study. "The map is just a grid that you can't really
interpret unless you put a model into it to see 'Ok, it looks like this
part is here, and that part is there, and this is how the protein is put
together.'"
Gres constructed the model, which surprisingly revealed "ordered" water molecules at areas between the viral proteins.
"We thought, 'How could some simple water molecules really be of
consequence?'" Sarafianos said. "But when we looked carefully, we
realized there are thousands of waters that help stabilize the complex
capsid scaffold. We hypothesized that this is an essential part of the
stability of the whole capsid assembly."
To test that hypothesis, they dehydrated the crystals using chemicals
and noticed that the proteins in them changed shape. This change
suggested that water molecules help the capsid shell to be flexible and
assume different forms, which is critical for the life cycle of the
virus, Sarafianos said.
The National Institutes of Health recently awarded the team a grant
of $2.28 million over five years to continue their study. Future studies
using the newly developed model will assist Sarafianos and his team as
they work toward developing antiviral drugs that combat the disease by
taking advantage of the new findings.
Story Source:
The above post is reprinted from
materials provided by
University of Missouri-Columbia.
Note: Materials may be edited for content and length.